SENIOR LEADERSHIP Since the previous review, there has been significant recruitment and promotion of key individuals to senior leadership positions to expand the Cancer Center leadership from five positions (Director and four Associate Directors) to eight. The Center Director, Theodore Krontiris, MD, PhD, in his capacity as Center Director and as Executive Vice President for Medical and Scientific Affairs of City of Hope, is the chief means by which all organizational entities and inherent capabilities are integrated in the research of the Cancer Center. As EVPMSA, he oversees the derivation and renewal of the Institutional strategic plan. Through his collaboration with, and oversight of, the COH Beckman Research Institute (BRI) Director and the COH National Medical Center (NMC) Chief Medical Officer, he assures that faculty hiring in the BRI and NMC, respectively, conforms to the strategic plan and is consonant with needs of the Cancer Center Programs?for expanding their interdisciplinary research activities, as well as addressing peer-review and external advisors'recommendations about the state of the Center. The Deputy Director, Richard Jove, PhD, recruited from H. Lee Moffitt Cancer Center, has substantial experience in leading translational research programs. He oversees the implementation of the overall Center strategy and has scientific oversight of Shared Resources. The AD for Administration, Michael Benedict, PharmD, oversees all office operations and CCSG management, and has administrative oversight of Shared Resources. Robert Figlin, MD, AD for Clinical Research, was recently recruited from UCLA. He oversees all clinical cancer activities and the coordination of all cancer clinical trials. Yun Yen, MD, PhD, is the AD for Translational Research, a new leadership position since the previous review. He is responsible for integrating correlative laboratory studies into clinical trials. In addition, Drs. Yen and Figlin co-chair the Task Force for Cancer Center Disease Program Development (see Essential Characteristics), which includes the Deputy Director and the other ADs as members. Smita Bhatia, MD, a national leader in cancer survivorship studies, was promoted to AD for Population Research and is responsible for developing research directions in cancer prevention and control. John Rossi, PhD, is a longtime leader in RNA biology and continues to foster successful interdisciplinary collaborations within the Cancer Center membership as part of his role as AD for Basic Research. Joyce Niland, PhD, with her outstanding experience in medical informatics, was appointed AD for Information Sciences, a new AD position concomitant with the increasing role of informatics in Cancer Center operations. In addition to the qualifications and roles of each of the Senior Leadership positions described on the following pages, many of these Cancer Center leaders are Division Chairs or Department Directors within BRI or NMC.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
City of Hope/Beckman Research Institute
United States
Zip Code
Slavin, Thomas P; Banks, Kimberly C; Chudova, Darya et al. (2018) Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. J Clin Oncol :JCO1800328
Yun, Xinwei; Zhang, Keqiang; Wang, Jinhui et al. (2018) Targeting USP22 Suppresses Tumorigenicity and Enhances Cisplatin Sensitivity Through ALDH1A3 Downregulation in Cancer-Initiating Cells from Lung Adenocarcinoma. Mol Cancer Res 16:1161-1171
Herrera, Alex F; Rodig, Scott J; Song, Joo Y et al. (2018) Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. Biol Blood Marrow Transplant 24:514-520
Oh, Eunjin; Ahn, Miwon; Afelik, Solomon et al. (2018) Syntaxin 4 Expression in Pancreatic ?-Cells Promotes Islet Function and Protects Functional ?-Cell Mass. Diabetes 67:2626-2639
Shahin, Sophia A; Wang, Ruining; Simargi, Shirleen I et al. (2018) Hyaluronic acid conjugated nanoparticle delivery of siRNA against TWIST reduces tumor burden and enhances sensitivity to cisplatin in ovarian cancer. Nanomedicine 14:1381-1394
Wittenberg, Elaine; Ferrell, Betty; Koczywas, Marianna et al. (2018) Pilot Study of a Communication Coaching Telephone Intervention for Lung Cancer Caregivers. Cancer Nurs 41:506-512
Zhang, Keqiang; Wang, Jinhui; Yang, Lu et al. (2018) Targeting histone methyltransferase G9a inhibits growth and Wnt signaling pathway by epigenetically regulating HP1? and APC2 gene expression in non-small cell lung cancer. Mol Cancer 17:153
Zhang, Bin; Nguyen, Le Xuan Truong; Li, Ling et al. (2018) Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia. Nat Med 24:450-462
Kirschbaum, Mark H; Frankel, Paul; Synold, Timothy W et al. (2018) A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium Study. Br J Haematol 180:445-448
Moreira, Dayson; Adamus, Tomasz; Zhao, Xingli et al. (2018) STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers. Clin Cancer Res 24:5948-5962

Showing the most recent 10 out of 1396 publications